Company Filing History:
1 out of 141 
1 out of 6 
1 out of 12 
Years Active: 2015-2023
Title: Stéphane Birkle: Innovator in Cancer Treatment
Introduction
Stéphane Birkle is a notable inventor based in Nantes, France. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 2 patents, Birkle's work focuses on the use of antibodies to enhance the therapeutic potential of drugs targeting specific cancer cells.
Latest Patents
Birkle's latest patents include a method for delivering an anti-cancer agent into cells expressing the O-acetylated GD2 ganglioside. This method utilizes an antibody that recognizes the O-acetylated GD2 ganglioside, thereby improving the efficacy of cancer treatments. Another significant patent involves the use of monoclonal antibodies that specifically target the O-acetylated form of GD2 ganglioside. This invention aims to diagnose and treat cancers where cells express the O-acetylated GD2, increasing diagnostic specificity and reducing treatment toxicity.
Career Highlights
Throughout his career, Stéphane Birkle has worked with esteemed institutions such as Université de Nantes and Ogd2 Pharma. His research has been pivotal in advancing the understanding and treatment of cancers associated with the O-acetylated GD2 ganglioside.
Collaborations
Birkle has collaborated with notable professionals in his field, including Jean-Marie Mussini and Jacques Aubry. These collaborations have further enriched his research and contributed to the development of his patented technologies.
Conclusion
Stéphane Birkle's innovative work in cancer treatment through the use of antibodies showcases his commitment to improving therapeutic strategies. His patents reflect a significant advancement in the fight against cancer, emphasizing the importance of targeted treatments.